Related Experiment Video
Updated: Apr 25, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study
Murat Kose1, Samim Emet2, Timur Selcuk Akpinar1
1Department of Internal Medicine, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey.
Insights
Serum endocan levels are significantly elevated in patients with acute coronary syndrome (ACS), indicating its potential as a biomarker for endothelial dysfunction in this condition.
Area of Science:
- Cardiology
- Biomarkers
- Endothelial Biology
Background:
- Endothelial-specific molecule 1 (endocan) is a proteoglycan primarily expressed in endothelial cells.
- Endothelial dysfunction plays a critical role in the pathophysiology of acute coronary syndrome (ACS).
Purpose of the Study:
- To investigate the association between serum endocan levels and the presence and characteristics of ACS.
- To evaluate endocan as a potential biomarker for endothelial pathology in ACS patients.
Main Methods:
- A case-control study involving 53 patients with ACS and 30 healthy controls.
- Serum endocan levels were measured and compared between groups.
- Coronary artery disease severity was assessed using Gensini and SYNTAX scores.
Main Results:
- Serum endocan levels were significantly higher in the ACS group compared to the control group (P = .014).
- Diabetic patients with ACS exhibited higher serum endocan levels than non-diabetic ACS patients (P = .016).
- No significant correlation was found between serum endocan levels and Gensini or SYNTAX scores.
Conclusions:
- Serum endocan levels are significantly elevated in patients with ACS, suggesting its role as a marker of endothelial pathology.
- Endocan may serve as a novel biomarker for identifying endothelial dysfunction in the context of ACS.
- Further research is warranted to explore the clinical utility of endocan in ACS management.
Abstract:
Endothelial-specific molecule 1 (endocan) is expressed in endothelial cells. We investigated the relationship between acute coronary syndrome (ACS) and serum endocan levels. We included 30 individuals as a control group and 53 patients diagnosed with ACS. The severity of coronary artery disease was assessed by a modified Gensini stenosis and SYNTAX scoring system. There was a significant difference in serum endocan levels between the control group and the ACS group (0.75 ± 0.13 vs 0.86 ± 0.25 ng/mL, P = .014). There was also a significant difference in serum endocan levels between diabetic patients with ACS and nondiabetic patients with ACS (1.02 ± 0.33 vs 0.81 ± 0.21 ng/mL, P = .016). There was no significant correlation between serum endocan level, Gensini, and SYNTAX score (r = .11, P = .53 and r = .16, P = .37). Endocan, a new biomarker of endothelial pathology, is significantly increased in patients with ACS.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease II: Pathophysiology

